Show simple item record

dc.contributor.authorZangarini, M
dc.contributor.authorBerry, P
dc.contributor.authorSludden, J
dc.contributor.authorRaynaud, FI
dc.contributor.authorBanerji, U
dc.contributor.authorJones, P
dc.contributor.authorEdwards, D
dc.contributor.authorVeal, GJ
dc.date.accessioned2019-06-27T11:03:40Z
dc.date.issued2017-07-10
dc.identifier.citationBioanalysis, 2017, 9 (13), pp. 1001 - 1010
dc.identifier.issn1757-6180
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3278
dc.identifier.eissn1757-6199
dc.identifier.doi10.4155/bio-2017-0043
dc.description.abstractAim SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma concentrations of SRA737 was validated.Methods & results Sample preparation involved protein precipitation with acetonitrile following addition of 13 C 15 N-deuterated SRA737 as internal standard. A rapid and selective method was fully validated across a range of 5-20,000 ng/ml, exhibiting good sensitivity, overall precision (expressed as coefficient of variation) ≤8.0% and accuracy 96-102%. Consistently high recovery was observed, with no matrix effect and a lower limit of quantitation of 5 ng/ml.Conclusion A novel method for analyzing SRA737 in human plasma has been validated and is now being utilized for quantification of SRA737 in a Phase I trial.
dc.formatPrint-Electronic
dc.format.extent1001 - 1010
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectProtein Kinase Inhibitors
dc.subjectBlood Chemical Analysis
dc.subjectChromatography, High Pressure Liquid
dc.subjectLinear Models
dc.subjectTandem Mass Spectrometry
dc.subjectLimit of Detection
dc.subjectHeterocyclic Compounds, 4 or More Rings
dc.subjectCheckpoint Kinase 1
dc.titleDevelopment and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.
dc.typeJournal Article
dcterms.dateAccepted2016-04-02
rioxxterms.versionofrecord10.4155/bio-2017-0043
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2017-07-10
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBioanalysis
pubs.issue13
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono)
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNot known
icr.researchteamClinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)en_US
icr.researchteamClinical Pharmacology – Adaptive Therapyen_US
icr.researchteamMedicine Drug Development Unit (de Bono)en_US
dc.contributor.icrauthorRaynaud, Florenceen
dc.contributor.icrauthorBanerji, Udaien
dc.contributor.icrauthorTurner, Lydiaen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record